Back to top
more

Novo Nordisk (NVO)

(Real Time Quote from BATS)

$48.80 USD

48.80
31,065,396

+3.42 (7.54%)

Updated Aug 7, 2025 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Novo Nordisk (NVO) Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2019.

Zacks Equity Research

NVS vs. NVO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

NVS vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Gilead-Galapagos Ink $5.1B Deal for Additional Compounds

by Zacks Equity Research

Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.

Kinjel Shah headshot

Pharma Stock Roundup: Pipeline & Regulatory Updates by MRK, GSK, SNY

by Kinjel Shah

Glaxo (GSK) provides updates on HIV regimens. FDA accepts Merck (MRK) & Sanofi's (SNY) regulatory applications for review.

Zacks Equity Research

Court Ruling Topples Trump Order, No Price Display in TV Ads

by Zacks Equity Research

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Zacks Equity Research

Novo Nordisk Reports Encouraging Data From Hemophilia Studies

by Zacks Equity Research

Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.

Zacks Equity Research

Lilly's Study on Higher Doses of Trulicity Meets Endpoint

by Zacks Equity Research

Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.

Zacks Equity Research

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

by Zacks Equity Research

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

Zacks Equity Research

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

by Zacks Equity Research

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

by Kinjel Shah

Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

Zacks Equity Research

Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs

by Zacks Equity Research

Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

Zacks Equity Research

NVS or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients

by Zacks Equity Research

Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

Kinjel Shah headshot

Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

by Kinjel Shah

Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

Zacks Equity Research

BMY or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BMY vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum

by Zacks Equity Research

Gilead (GILD) up 6.9% in the year so far on strong performance of HIV franchise and pipeline development efforts.

Zacks Equity Research

Lilly (LLY) Launches Half-Priced Version of Humalog Insulin

by Zacks Equity Research

Eli Lilly (LLY) offers a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Zacks Equity Research

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Zacks Equity Research

Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1

by Zacks Equity Research

Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.

Zacks Equity Research

What's in the Cards for AEterna (AEZS) This Earnings Season?

by Zacks Equity Research

AEterna (AEZS) may provide update on the path forward for Macrilen in Europe on the first-quarter earnings call.

Zacks Equity Research

Why Earnings Season Could Be Great for Novo Nordisk (NVO)

by Zacks Equity Research

Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Can Allergan (AGN) Beat Earnings Estimates Again in Q1?

by Zacks Equity Research

Allergan's (AGN) key products like Botox are likely to provide top-line support in Q1 as loss of exclusivity of several products hurts sales

Zacks Equity Research

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

Zacks Equity Research

What's in Store for BioSpecifics (BSTC) This Earnings Season?

by Zacks Equity Research

BioSpecifics Technologies (BSTC) will provide updates on Xiaflex and pipeline progress, when it releases first-quarter 2019 results.